Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $71.04 -1.87 (-2.56%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$70.19▼$73.2250-Day Range$62.00▼$79.0152-Week Range$21.92▼$80.53Volume1.75 million shsAverage Volume2.46 million shsMarket Capitalization$10.56 billionP/E RatioN/ADividend YieldN/APrice Target$79.19 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insmed alerts: Email Address Insmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside11.5% Upside$79.19 Price TargetShort InterestHealthy9.08% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.47Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.42) to ($4.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.56 out of 5 starsMedical Sector215th out of 910 stocksPharmaceutical Preparations Industry90th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.08% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insmed has recently decreased by 1.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 68.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.28. Previous Next 1.4 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Insmed this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -54% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($5.42) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -13.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -13.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 308.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insmed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Insmed Stock (NASDAQ:INSM)Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesSeptember 6 at 8:00 AM | prnewswire.comInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 4 at 2:05 AM | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Receives Consensus Rating of "Buy" from BrokeragesSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 30, 2024 | markets.businessinsider.comInsmed’s Brensocatib Poised for Market Leadership: A Buy Rating Amidst Unthreatening CompetitionAugust 30, 2024 | americanbankingnews.comCantor Fitzgerald Analysts Lower Earnings Estimates for Insmed Incorporated (NASDAQ:INSM)August 30, 2024 | americanbankingnews.comInsmed's (INSM) "Buy" Rating Reaffirmed at HC WainwrightAugust 29, 2024 | finance.yahoo.comInsmed (INSM) Rose Due to Positive Trial ResultsAugust 28, 2024 | seekingalpha.comInsmed: Brensocatib Propels Stock As Regulatory Milestones ApproachSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 26, 2024 | benzinga.com$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much TodayAugust 26, 2024 | sg.finance.yahoo.comInsmed Incorporated (0JAV.L)August 24, 2024 | investors.comMeta Stock Leads 5 Names Near Buy Points As Market BouncesAugust 17, 2024 | ca.finance.yahoo.comINSM Sep 2024 72.500 callAugust 17, 2024 | ca.finance.yahoo.comINSM Sep 2024 70.000 putAugust 17, 2024 | ca.finance.yahoo.comINSM Sep 2024 62.500 callAugust 16, 2024 | seekingalpha.comTNA: It Might Be Time To Invest In Small-CapsAugust 15, 2024 | finance.yahoo.comInsider Sale: Chief People Strategy Officer Schaeffer Orlov S Nicole Sells Shares of Insmed Inc ...August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Breakthrough Trials and Market Expansion OpportunitiesSee More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$79.19 High Stock Price Target$102.00 Low Stock Price Target$42.00 Potential Upside/Downside+11.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-244.27% Pretax Margin-243.37% Return on EquityN/A Return on Assets-57.00% Debt Debt-to-Equity Ratio25.05 Current Ratio2.71 Quick Ratio2.53 Sales & Book Value Annual Sales$328.61 million Price / Sales32.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book308.87Miscellaneous Outstanding Shares148,605,000Free Float141,769,000Market Cap$10.56 billion OptionableOptionable Beta1.11 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsArena PharmaceuticalsNASDAQ:ARNAForty SevenNASDAQ:FTSVChemoCentryxNASDAQ:CCXIPTC TherapeuticsNASDAQ:PTCTSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsMaven Securities LTDBought 5,000 shares on 8/29/2024Ownership: 0.003%Clearbridge Investments LLCBought 714,539 shares on 8/27/2024Ownership: 1.107%Dana Investment Advisors Inc.Sold 714 shares on 8/27/2024Ownership: 0.015%Teachers Retirement System of The State of KentuckyBought 9,400 shares on 8/26/2024Ownership: 0.006%Truist Financial CorpBought 6,166 shares on 8/21/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $30.99 at the start of the year. Since then, INSM stock has increased by 129.2% and is now trading at $71.04. View the best growth stocks for 2024 here. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing analysts' consensus estimates of ($1.22) by $0.72. The company's revenue for the quarter was up 17.0% on a year-over-year basis. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. Who are Insmed's major shareholders? Insmed's top institutional investors include Darwin Global Management Ltd. (2.38%), William Blair Investment Management LLC (2.33%), Principal Financial Group Inc. (1.12%) and Clearbridge Investments LLC (1.11%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, Martina MD Flammer, Michael Alexander Smith, Orlov S Nicole Schaeffer and David R Brennan. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD) and OPKO Health (OPK). This page (NASDAQ:INSM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
